Plus Therapeutics (NASDAQ:PSTV) Releases Earnings Results, Misses Expectations By $0.43 EPS

Plus Therapeutics (NASDAQ:PSTV) issued its quarterly earnings results on Friday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.43), FiscalAI reports. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The business had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.11 million.

Plus Therapeutics Stock Performance

Shares of NASDAQ:PSTV remained flat at $3.70 during midday trading on Friday. The stock had a trading volume of 62,111 shares, compared to its average volume of 116,506. The company has a market capitalization of $25.47 million, a P/E ratio of -1.61 and a beta of 1.40. Plus Therapeutics has a 1 year low of $2.90 and a 1 year high of $23.42. The stock’s 50 day moving average price is $4.12 and its 200 day moving average price is $5.44.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PSTV. Ascendiant Capital Markets lowered their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating for the company in a report on Monday, June 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $56.40.

Institutional Investors Weigh In On Plus Therapeutics

Large investors have recently bought and sold shares of the business. Susquehanna International Group LLP bought a new position in Plus Therapeutics during the 3rd quarter valued at about $46,000. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics in the second quarter worth approximately $41,000. Scientech Research LLC bought a new stake in shares of Plus Therapeutics in the third quarter worth approximately $100,000. XTX Topco Ltd purchased a new position in shares of Plus Therapeutics during the fourth quarter valued at approximately $127,000. Finally, State Street Corp raised its holdings in shares of Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after purchasing an additional 127,000 shares during the last quarter. 3.28% of the stock is currently owned by institutional investors.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.